PD60: Prostate Cancer: Detection & Screening VII

5/6/2019

7:00 AM - 9:00 AM

Location: MCP: W185d

Abstract Presenter(s)

Gerald Andriole, Jr., MD

Department Head
Washington University in Saint Louis
FB

Francesco Barletta
Maria Becerra, MD

University of Miami Miller School of Medicine
LC

Leo Chen, MD

Stanford
Cosimo De Nunzio

Department of Urology, Ospedale Sant'andrea, Sapienza University
FD

Frank-Jan Drost, MD

Erasmus MC University Medical Center
WE

William Ellis

Slides
Michael Gorin, MD

Johns Hopkins University School of Medicine
Christopher Khoo, MD,MBBS

Imperial Prostate, Imperial College London
John Lam, MD, MBA, FACS

Southern California Permanente Medical Group
Michael Liss, MD, MAS, FACS

University of Texas Health San Antonio
AS

Armando Stabile

Presentations:

7:00 AM - 7:10 AM
Likert vs. PI-RADS v2: A Comparison of Two Radiological Scoring Systems for Detection of Clinically Significant Prostate Cancer
Christopher Charles Khoo, MD,MBBS
7:10 AM - 7:20 AM
Can the time interval between MRI and Fusion Biopsy affect the Cancer Detection Rates?
Maria F. Becerra, MD
7:20 AM - 7:30 AM
Should we rely on multiparametric MRI of the prostate performed at non-Academic Centres? Implications for optimized target biopsy approaches
Francesco Barletta
7:30 AM - 7:40 AM
Prostate MRI, with or without targeted biopsy, and standard biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis.
Frank-Jan Hendrik Drost, MD
7:40 AM - 7:50 AM
Automated detection of prostate cancer on multiparametric MRI using deep neural networks trained on spatial coordinates and pathology of biopsy cores
Leo Chen, MD
7:50 AM - 8:00 AM
Using machine learning tools to predict prostate cancer upgrading after robotic radical prostatectomy
Cosimo De Nunzio
8:00 AM - 8:10 AM
Do performance characteristics of multi-parametric MRI of the prostate change according to patient age? Clinical implications for age-tailored biopsy approaches
Armando Stabile
8:10 AM - 8:20 AM
BRCA Mutations in Hispanic Men with First Degree Prostate and Breast Cancer History
Michael A. Liss, MD, MAS, FACS
8:20 AM - 8:30 AM
ROLE AND VALUE OF SECOND OPINION REVIEWS IN DNA METHYLATION POSITIVE EPIGENETIC ASSAYS IN NEGATIVE HISTOPATHOLGICAL PROSTATE BIOPSIES
John Stephen Lam, MD, MBA, FACS
8:30 AM - 8:40 AM
A PrOspective Phase 2/3 Multi-Center Study of ¹⁸F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer – Examination of Diagnostic AccuracY (OSPREY)
Michael A. Gorin, MD
8:40 AM - 8:50 AM
A Phase 3 Study to Evaluate the Safety and Efficacy of ^99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
William J. Ellis
8:50 AM - 9:00 AM
Sites of prostate cancer recurrence delineated with ¹⁸F-fluciclovine positron emission tomography in patients with negative or equivocal conventional imaging
Gerald L. Andriole, Jr., MD – Washington University Sch of Medicine